Subscribe to RSS
DOI: 10.1055/s-2007-959329
© Georg Thieme Verlag KG Stuttgart · New York
Arsentrioxid: „ein erfolgreiches Gift” bei Patienten mit akuter Promyelozytenleukämie
Arsenic trioxide: a „successful poison” in patients with acute promyelocytic leukemiaPublication History
eingereicht: 13.9.2006
akzeptiert: 17.1.2007
Publication Date:
07 February 2007 (online)

Zusammenfassung
Die Wirksamkeit von Arsenderivaten bei Neoplasien beruht auf komplexen Mechanismen. Bei der Therapie der akuten Promyelozytenleukämie (APL) steht ein dualer, zur Differenzierung und Apoptose der Blasten führender Effekt im Vordergrund.
Diese Zusammenfassung gibt einen Überblick über Aspekte der Pharmakologie, klinische Effizienz und unerwünschte Effekte von Arsentrioxid (ATO) bei APL. In 17 internationalen Studien zur Primär- und Rezidivtherapie mit ATO wurden insgesamt 565 Patienten eingeschlossen. Von den Patienten mit rezidivierter APL (n = 266) erreichten insgesamt 85,7 % eine Remission bei guter Verträglichkeit von ATO. Das Überleben nach 2 Jahren lag bei 50 bis 77 %. Bei neu diagnostizierter APL (n = 299) wurden Remissionsraten zwischen 73 und 95 % erreicht. Blutungskomplikationen, überwiegend zerebral, umfassten 66 % der Frühtodesfälle und waren die häufigste Todesursache. Die häufigste unerwünschte Begleiterscheinung von ATO war das APL-Differenzierungssyndrom bei bis zu 25 % der Patienten. Bei kurzen Beobachtungszeiten sind Langzeiteffekte noch nicht einschätzbar.
ATO erweist sich als hocheffizient in der Behandlung der APL. Es ist für die rezidivierte und refraktäre APL zugelassen.
Summary
he mechanism of action of arsenic derivates in neoplasitic disease is complex. Cell differentiation and apoptosis are of utmost importance in the therapy of acute promyelocytic leukemia (APL). This review considers essential aspects of the pharmacology, clinical efficacy and adverse effects of arsenic trioxide (ATO) in APL. So far ATO treatment has been investigated in 17 international studies encompassing 565 patients with either initially diagnosed or relapsed APL. 85.7% of patients with relapsed APL (n=266) had a remission and ATO was well tolerated. The overall survival after two years ranged from 50 to 77%. In the initial therapy of APL (n=299), complete remission was achieved in 73 to 95% of patients. The most frequent cause of death (66% of early deaths) was bleeding complications, mostly cerebral bleedings. The most common adverse effect of ATO (in up to 25% of patients) was the APL-differentiation syndrome. Because of the short follow-up periods, long-term effects cannot as yet be evaluated. Arsenic trioxide (ATO) is highly efficacious in the treatment of APL. Its use has been approved for relapsed and refractory APL.
Schlüsselwörter
Arsentrioxid - Promyelozytenleukämie
Key words
arsenic toxide - promyelocytic leukemia
Literatur
- 1
Au W Y, Chim C S, Lie A K, Liang R, Kwong Y L.
Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic
leukaemia recurring from previous relapses successfully treated using arsenic trioxide.
Br J Haematol.
2002;
117
130-132
MissingFormLabel
- 2
Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H.
Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment
of acute myeloid leukaemia?.
Br J Haematol.
2001;
112
783-786
MissingFormLabel
- 3
Camacho L H, Soignet S L, Chanel S. et al .
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia
treated with arsenic trioxide.
J Clin Oncol.
2000;
18
2620-2625
MissingFormLabel
- 4
Carmosino I, Latagliata R, Avvisati G. et al .
Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
Haematologica.
2004;
89
615-617
MissingFormLabel
- 5
Chen G Q, Shi X G, Tang W. et al .
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL):
I. As2O3 exerts dose-dependent dual effects on APL cells.
Blood.
1997;
89
3345-3353
MissingFormLabel
- 6
Chou W C, Hawkins A L, Barrett J F, Griffin C A, Dang C V.
Arsenic inhibition of telomerase transcription leads to genetic instability.
J Clin Invest.
2001;
108
1541-1547
MissingFormLabel
- 7
De Botton S, Fawaz A, Chevret S. et al .
Autologous and allogeneic stem-cell transplantation as salvage treatment of acute
promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective
analysis of the European acute promyelocytic leukemia group.
J Clin Oncol.
2005;
23
120-126
MissingFormLabel
- 8
Degos L, Dombret H, Chomienne C. et al .
All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic
leukemia.
Blood.
1995;
85
2643-2653
MissingFormLabel
- 9
Douer D, Hu W, Giralt S, Lill M, DiPersio J.
Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting
of hematopoietic stem cell transplantation.
Oncologist.
2003;
8
132-140
MissingFormLabel
- 10
Douer D, Tallman M S.
Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
J Clin Oncol.
2005;
23
2396-2410
MissingFormLabel
- 11
Doyle A C.
Notes of a case of leukocythaemia.
Lancet.
1882;
119
490
MissingFormLabel
- 12
Estey E, Garcia-Manero G, Ferrajoli A. et al .
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy
in untreated acute promyelocytic leukemia.
Blood.
2006;
107
3469-3473
MissingFormLabel
- 13
Forkner C E, Scott T F.
Arsenic as a therapeutic agent in chronic myelogenous leukemia.
JAMA.
1931;
97
3-5
MissingFormLabel
- 14
Frankel S R, Eardley A, Lauwers G, Weiss M, Warrell R P.
The „retinoic acid syndrome” in acute promyelocytic leukemia.
Ann Intern Med.
1992;
117
292-296
MissingFormLabel
- 15
George B, Mathews V, Poonkuzhali B, Shaji R V, Srivastava A, Chandy M.
Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic
trioxide: a single center experience.
Leukemia.
2004;
18
1587-1590
MissingFormLabel
- 16
Ghavamzadeh A, Alimoghaddam K, Ghaffari S H. et al .
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or
chemotherapy.
Ann Oncol.
2006;
17
131-134
MissingFormLabel
- 17
Helwig A, Klemm M, Schuttig R. et al .
Arsenic-induced APL differentiation in cerebrospinal fluid.
Leuk Res.
2006;
, Epub ahead of print
MissingFormLabel
- 18
Jing Y, Wang L, Xia L. et al .
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic
leukemia cells in vitro and in vivo.
Blood.
2001;
97
264-269
MissingFormLabel
- 19
Kai T, Kimura H, Shiga Y, Ogawa K, Sato H, Maruyama Y.
Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic
stem cell transplantation: successful treatment by arsenic trioxide in combination
with local radiotherapy.
Int J Hematol.
2006;
83
337-340
MissingFormLabel
- 20
Kwong Y L, Au W Y, Chim C S, Pang A, Suen C, Liang R.
Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic
leukaemia: clinicopathological and molecular features of a pilot study.
Am J Hematol.
2001;
66
274-279
MissingFormLabel
- 21
Lazo G, Kantarjian H, Estey E, Thomas D, O’Brien S, Cortes J.
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic
leukemia: the M. D. Anderson experience.
Cancer.
2003;
97
2218-2224
MissingFormLabel
- 22
Lengfelder E, Gnad U, Büchner T, Hehlmann R.
Treatment of relapsed acute promyelocytic leukemia.
Onkologie.
2003;
26
373-379
MissingFormLabel
- 23
Lengfelder E, Hehlmann R, Büchner T.
Aktuelle Therapiekonzepte bei akuter Promyelozytenleukämie.
Dtsch Med Wochenschr.
2001;
126
1073-1079
MissingFormLabel
- 24
Lengfelder E, Saussele S, Weisser A, Büchner T, Hehlmann R.
Treatment concepts of acute promyelocytic leukemia.
Crit Rev Oncol Hematol.
2005;
56
261-274
MissingFormLabel
- 25
Leoni F, Gianfaldoni G, Annunziata M. et al .
Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
Haematologica.
2002;
87
485-489
MissingFormLabel
- 26
Lu D P, Qiu J Y, Jiang B. et al .
Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot
report.
Blood.
2002;
99
3136-3143
MissingFormLabel
- 27
Mathews V, George B, Lakshmi K M. et al .
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic
leukemia: durable remissions with minimal toxicity.
Blood.
2006;
107
2627-2632
MissingFormLabel
- 28
Miller W H, Schipper H M, Lee J S, Singer J, Waxman S.
Mechanisms of action of arsenic trioxide.
Cancer Res.
2002;
62
3893-3903
MissingFormLabel
- 29
Niu C, Yan H, Yu T. et al .
Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission
induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed
acute promyelocytic leukemia patients.
Blood.
1999;
94
3315-3324
MissingFormLabel
- 30
Ohnishi K, Yoshida H, Shigeno K. et al .
Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic
leukemia: need for careful electrocardiogram monitoring.
Leukemia.
2002;
16
617-622
MissingFormLabel
- 31
Raffoux E, Rousselot P, Poupon J. et al .
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with
relapsed acute promyelocytic leukemia.
J Clin Oncol.
2003;
21
2326-2334
MissingFormLabel
- 32
Roboz G J, Dias S, Lam G. et al .
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may
exert an antileukemic effect via inhibition of angiogenesis.
Blood.
2000;
96
1525-1530
MissingFormLabel
- 33
Sanz M A, Arcese W, de la Rubia J. et al .
Stem cell transplantation for acute promyelocytic leukemia in the ATRA era: A survey
of the European Blood and Marrow Transplantation Group.
Blood.
2000;
96
522a
MissingFormLabel
- 34
Sanz M A, Fenaux P, LoCoco F.
Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current
evidence.
Haematologica.
2005;
90
1231-1235
MissingFormLabel
- 35
Shen Y, Shen Z X, Yan H. et al .
Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide
in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional
dosage.
Leukemia.
2001;
15
735-741
MissingFormLabel
- 36
Shen Z X, Chen G Q, Ni J H. et al .
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL):
II. Clinical efficacy and pharmacokinetics in relapsed patients.
Blood.
1997;
89
3354-3360
MissingFormLabel
- 37
Shen Z X, Shi Z Z, Fang J. et al .
All-trans retinoic acid/ As2O3 combination yields a high quality remission and survival
in newly diagnosed acute promyelocytic leukemia.
Proc Natl Acad Sci U S A.
2004;
101
5328-5335
MissingFormLabel
- 38
Shigeno K, Naito K, Sahara N. et al .
Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic
leukemia: updated outcomes of the phase II study and postremission therapies.
Int J Hematol.
2005;
82
224-229
MissingFormLabel
- 39
Siu C W, Au W Y, Yung C. et al .
Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic
leukemia: implications for long-term cardiac safety.
Blood.
2006;
108
103-106
MissingFormLabel
- 40
Soignet S L, Frankel S R, Douer D. et al .
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic
leukemia.
J Clin Oncol.
2001;
19
3852-3860
MissingFormLabel
- 41
Soignet S L, Maslak P, Wang Z G. et al .
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
N Engl J Med.
1998;
339
1341-1348
MissingFormLabel
- 42
Tallman M S, Nabhan C, Feusner J H, Rowe J M.
Acute promyelocytic leukemia: evolving therapeutic strategies.
Blood.
2002;
99
759-767
MissingFormLabel
- 43
Thomas X, Dombret H, Cordonnier C. et al .
Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy
followed by timed sequential chemotherapy and stem cell transplantation. APL Study
Group. Acute promyelocytic leukemia.
Leukemia.
2000;
14
1006-1013
MissingFormLabel
- 44
Thomas X, Pigneux A, Raffoux E, Huguet F, Caillot D, Fenaux P.
Superiority of an arsenic trioxide-based regimen over a historic control combining
all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute
promyelocytic leukemia.
Haematologica.
2006;
91
996-997
MissingFormLabel
- 45 Trisenox. Summary of Product Characteristics 2002;. Cell Therapeutics Europe 5
MissingFormLabel
- 46
Tsimberidou A M, Estey E, Whitman G J. et al .
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful
treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin
therapies.
Leuk Res.
2004;
28
991-994
MissingFormLabel
- 47
Unnikrishnan D, Dutcher J P, Varshneya N. et al .
Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
Blood.
2001;
97
1514-1516
MissingFormLabel
- 48
Wang Z, Zhou J, Lu X, Gong Z, Le X C.
Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing
arsenic trioxide treatment.
Chem Res Toxicol.
2004;
17
95-103
MissingFormLabel
- 49
Westervelt P, Brown R A, Adkins D R. et al .
Sudden death among patients with acute promyelocytic leukemia treated with arsenic
trioxide.
Blood.
2001;
98
266-271
MissingFormLabel
- 50
Zhang P, Wang S, Hu L. et al .
Seven years’ summary report on the treatment of acute promyelocytic leukemia with
arsenic trioxide - an analysis of 242 cases.
Zhonghua Xue Ye Xue Za Zhi.
2000;
21
67-70
MissingFormLabel
- 51
Zhu J, Koken M H, Quignon F. et al .
Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment
of acute promyelocytic leukemia.
Proc Natl Acad Sci U S A.
1997;
94
3978-3983
MissingFormLabel
Priv.-Doz. Dr. Eva Lengfelder
III. Medizinische Universitätsklinik Mannheim
Wiesbadener Straße 7-11
68305 Mannheim
Phone: +49/621/3834110
Fax: +49/621/3834201
Email: eva.lengfelder@med3.ma.uni-heidelberg.de